Charles R.  Kummeth net worth and biography

Charles Kummeth Biography and Net Worth

CEO of Bio-Techne
Chuck Kummeth became President and Chief Executive Officer of Bio-Techne Corporation on April 1, 2013. Prior to joining the Company, he served as President of Mass Spectrometry and Chromatography at Thermo Fisher Scientific Inc. and was President of that company’s Laboratory Consumables Division from 2009 to September 2011. Prior to joining Thermo Fisher, Mr. Kummeth served in various leadership roles during his 24 year career at 3M Corporation, most recently as the Vice President of the company’s Medical Division from 2006 to 2008 and as the Managing Director of 3M for the UK and Ireland.

Mr. Kummeth received a Master of Science in Software Engineering & Design from the University of St. Thomas and a Master of Business Administration from the Carlson School of Business at the University of Minnesota. He is a graduate of the University of North Dakota, where he received a Bachelor of Science in Electrical Engineering. Mr. Kummeth serves on the board of Gentherm.

What is Charles R. Kummeth's net worth?

The estimated net worth of Charles R. Kummeth is at least $86.85 million as of July 21st, 2023. Mr. Kummeth owns 1,258,766 shares of Bio-Techne stock worth more than $86,854,854 as of December 11th. This net worth approximation does not reflect any other assets that Mr. Kummeth may own. Additionally, Mr. Kummeth receives a salary of $1,260,000.00 as CEO at Bio-Techne. Learn More about Charles R. Kummeth's net worth.

How old is Charles R. Kummeth?

Mr. Kummeth is currently 63 years old. There are 5 older executives and no younger executives at Bio-Techne. Learn More on Charles R. Kummeth's age.

What is Charles R. Kummeth's salary?

As the CEO of Bio-Techne Co., Mr. Kummeth earns $1,260,000.00 per year. Learn More on Charles R. Kummeth's salary.

How do I contact Charles R. Kummeth?

The corporate mailing address for Mr. Kummeth and other Bio-Techne executives is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. Bio-Techne can also be reached via phone at (612) 379-8854 and via email at [email protected]. Learn More on Charles R. Kummeth's contact information.

Has Charles R. Kummeth been buying or selling shares of Bio-Techne?

Charles R. Kummeth has not been actively trading shares of Bio-Techne during the past quarter. Learn More on Charles R. Kummeth's trading history.

Who are Bio-Techne's active insiders?

Bio-Techne's insider roster includes Robert Baumgartner (Director), Norman Eansor (Insider), Brenda Furlow (SVP), John Higgins (Director), James Hippel (CFO), Kim Kelderman (Insider), Charles Kummeth (CEO), Roeland Nusse (Director), and Alpna Seth (Director). Learn More on Bio-Techne's active insiders.

Are insiders buying or selling shares of Bio-Techne?

In the last twelve months, insiders at the biotechnology company sold shares 2 times. They sold a total of 88,939 shares worth more than $7,786,780.48. The most recent insider tranaction occured on August, 30th when Director Roeland Nusse sold 8,939 shares worth more than $717,980.48. Insiders at Bio-Techne own 4.5% of the company. Learn More about insider trades at Bio-Techne.

Information on this page was last updated on 8/30/2023.

Charles R. Kummeth Insider Trading History at Bio-Techne

See Full Table

Charles R. Kummeth Buying and Selling Activity at Bio-Techne

This chart shows Charles R. Kummeth's buying and selling at Bio-Techne by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Bio-Techne Company Overview

Bio-Techne logo
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Read More

Today's Range

Now: $69.00
Low: $68.31
High: $69.33

50 Day Range

MA: $63.08
Low: $52.83
High: $69.41

2 Week Range

Now: $69.00
Low: $51.79
High: $89.91


1,162,336 shs

Average Volume

1,018,403 shs

Market Capitalization

$10.91 billion

P/E Ratio


Dividend Yield